Abstract
The case of a 69-year-old woman who developed muscle weakness on chronic amiodarone treatment is reported. Muscle biopsy showed vacuolar alterations and a marked accumulation of amiodarone and of its metabolite desethylamiodarone was found in the muscle sample despite normal blood levels. Amiodarone-induced morphological alterations of the muscle may be related to the actual tissue concentration rather than to the blood level.
Sommario
Viene presentato il caso di una donna di 69 anni che sviluppò una diffusa ipostenia muscolare durante trattamento cronico con amiodarone. La biopsia muscolare dimostrò alterazioni vacuolari nelle fibre e fu riscontrato un marcato accumulo di amiodarone e del suo metabolita disetilamiodarone nel muscolo nonostante valori ematici normali. Si avanza l'ipotesi che le alterazioni muscolari indotte dall'amiodarone siano correlabili alle concentrazioni tissutali piuttosto che ai livelli ematici.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borowski G.D., Garofano C.D., Rose L.I., Spielman S.R., Rotmensch H.R., Greenspan A.M., Horowitz L.N.:Effect of long-term Amiodarone therapy. Am. J. Med 78: 443–50, 1985.
Charness M.E., Morady F., Scheinman M.M.:Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34: 669–71, 1984.
Fedorko M.E., Hirsch J.G., Cohn Z.A.:Autophagic vacuoles produced in vitro. I. Studies on cultured macrophages exposed to chloroquine. J Cell Biol. 37:377–91, 1968.
Fedorko M.E., Hirsch J.G., Cohn Z.A.:Autophagic vacuoles produced in vitro. II. Studies on the mechanism of formation of autophagic vacuoles produced by chloroquine. J Cell Biol 38:392–402, 1968.
Heath M.F., Costa-Jussa F.R., Jacobs J.M., Jacobson W.:The induction of pulmonary phospholipidosis and the inhibition of lysosomal phaspholipases by amiodarone. Br J Exp Pathol 66:391–98, 1985.
Heger J, Prystowsky E, Zipes D.:Relationship between amiodarone dosage, drug concentrations, and adverse side-effects. Am. Heart. J. 106:931–35, 1983.
Layzer R.B.:Neuromuscular manifestations of systemic disease. F.A. Davis Company Philadelphia: 88, 1985.
Maggioni A.P., Maggi A., Volpi A., D'Aranno V., Tognoni G., Giani P.:Amiodarone distribution in human tissues after sudden death during Holter recording. Am J Cardiol 52:217–18, 1983.
Martinez-Arizala A., Sobol S.M., McCarty G.E., Nichols B.R., Rakita L.:Amiodarone neuropathy. Neurology 33:643–5, 1983.
Meier C., Kauer B., Mueller U., Ludin H.P.:Neuromyopathy during chronic amiodarone treatment. J. Neurol 220:231–39, 1979.
Storey G., Adams P., Campbell R., Holt D.:High performance liquid chromatographic measurements of amiodarone and desethylamiodarone in small tissues samples after enzymatic digestion. J Clin. Pathol. 36:785–89, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carella, F., Riva, E., Morandi, L. et al. Myopathy during amiodarone treatment: a case report. Ital J Neuro Sci 8, 603–608 (1987). https://doi.org/10.1007/BF02333668
Issue Date:
DOI: https://doi.org/10.1007/BF02333668